Keywords: novacea, stops, ph, iii, asentar, trial, usa-based

Novacea stops Ph III Asentar trial

Article | 12 November 2007

USA-based biopharmaceutical firm Novacea has stopped a Phase III trial of its prostate cancer therapy Asentar (DN-101), co-developed with Schering-Plough, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Schering Plough

Schering-Plough

Go to company listing

Related Drugs

docetaxel

Taxotere

Go to drug listing